 Jaguar Health Inc NASDAQ: JAGX announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea CID. The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab, and a taxane. 